
GLS
Healthcare · Biotechnology · $11.6M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2022
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 10, 2023 | Before the open | -0.15 | -0.07 | +53.4% |
| Mar 28, 2023 | Before the open | -0.26 | -0.33 | -28.8% |
| Nov 14, 2022 | Before the open | -0.34 | -0.20 | +41.2% |
| Sep 16, 2022 | Before the open | — | -0.17 | — |
| Jun 8, 2022 | Time not confirmed | — | -0.60 | — |
| Mar 24, 2022 | After the close | — | -0.27 | — |
| Nov 16, 2021 | Time not confirmed | — | -0.41 | — |
| Jul 8, 2021 | Time not confirmed | — | -0.44 | — |
| Nov 13, 2020 | Time not confirmed | — | -0.00 | — |
Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops…